Smith & Nephew: are shares in this FTSE 100 company a buy?

Smith+Nephew is a FTSE 100 company that has been rocked by the pandemic, but early signs point to recovery. Is it a good investment opportunity?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The medical device industry – often seen as the poor relation of the pharmaceuticals and healthcare space – suffered in 2020. Elective routine surgical procedures took a back seat for most of last year, but now that the Covid-19 vaccine programme is gaining pace, things are looking up for one FTSE 100 company.

The share price for Smith & Nephew (LSE: SN) has grown 15% over the last six weeks alone, and still has some way to go, if its pre-pandemic stock valuation is anything to go by. This, together with the fact that the company has never yet failed to pay out a dividend since it was first listed back in the 1930s, leads me to give it serious consideration as an addition to my investment portfolio.        

Smith & Nephew operates across three segments – orthopaedics, sports medicine and ENT (ear, nose, and throat), and advanced wound management, and while the company is not a leader in any of these, it is in the top three across the board. Geographically, Smith & Nephew draws most of its business from the US (50%) and Europe (20%). Back in 2019, the stock of this FTSE 100 company was showing real momentum on the back of overcoming some fairly tortuous changes in personnel and leadership, and the growing pains that come from inorganic growth. But then the pandemic happened, and revenue growth for the whole year hit a wall.

Smith & Nephew’s Q1 sales call, however, was tentatively positive. Revenues were up in Q1 2021 across all three franchise segments, driven by a genuine increase in surgical volumes, and totalled $1.3 billion, representing 6.3% underlying revenue growth. Within orthopaedics, hip options were consistently the most resilient to Covid-19, likely owing to such procedures being more challenging to delay. Sports medicine has shown the most rapid recovery, ascribed to a combination of the outpatient setting, younger patient mix, and the acute nature of the injuries, rendering such procedures the most amenable to this period of Covid-19 transition.

This FTSE 100 company expects Q1 trends to pick up through the year, and lead to a 10-13% growth in 2021 revenues, with the majority of growth organic. The outlook assumes no Covid-19 constraints on surgical procedures in H2 2021, and in many ways is predicated on the incumbent health-care systems being sufficiently able tooled up to deal with pent-up demand. Early indications point to faster normalisation being likely in the highly decentralised US, with the more centralised healthcare systems of Europe slower to respond.

Smith & Nephew also needs to execute on the successful integration of recent acquisitions. In January 2020, the company acquired Tusker Medical Inc. which bought with it an ENT system (Tula), the launch of which was considerably impacted by the pandemic. More recently, Smith & Nephew acquired the Extremity Orthopaedics business from Integra LifeSciences Holdings Corporation for $240M. Despite the downturn of last year, Smith & Nephew has continued to invest in R&D, and has a number of home-grown launches to roll-out, in what remains a challenging environment where stakeholder engagement opportunities remain limited.

Overall, Smith & Nephew is a FTSE 100 company that I’m inclined to invest in as I believe the share price has room for growth, and the dividend return is reliable. 2020 was the first year in many where the dividend was flat rather than growing, but my expectation is that dividend growth will return.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Pam Narang owns no shares in any company mentioned. The Motley Fool UK has recommended Smith & Nephew. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »